The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Vepdegestrant, a PROTAC estrogen receptor (ER) degrader, vs fulvestrant in ER-positive/human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer: Results of the global, randomized, phase 3 VERITAC-2 study.
 
Erika Hamilton
Consulting or Advisory Role - Accutar Biotechnology (Inst); Arvinas (Inst); AstraZeneca (Inst); Circle Pharma (Inst); Daiichi Sankyo (Inst); Ellipses Pharma (Inst); Entos (Inst); Fosun Pharma (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Janssen (Inst); Jazz Pharmaceuticals (Inst); Jefferies (Inst); Johnson and Johnson (Inst); Lilly (Inst); Medical Pharma Services (Inst); Mersana (Inst); Novartis (Inst); Olema Pharmaceuticals (Inst); Pfizer (Inst); Stemline Therapeutics (Inst); Tempus (Inst); Theratechnologies (Inst); Tubulis GmbH (Inst); Verascity Science (Inst); Zentalis (Inst)
Research Funding - Abbvie (Inst); Accutar Biotech (Inst); Acerta Pharma (Inst); ADC Therapeutics (Inst); Akeso Biopharma (Inst); Amgen (Inst); Aravive (Inst); ArQule (Inst); Artios (Inst); Arvinas (Inst); AstraZeneca (Inst); AtlasMedx (Inst); BeiGene (Inst); Black Diamond Therapeutics (Inst); Bliss Biopharmaceutical (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squib (Inst); Cascadian Therapeutics (Inst); Clovis Oncology (Inst); Compugen (Inst); Context Therapeutics (Inst); Cullinan Oncology (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dana Farber Cancer Hospital (Inst); Dantari (Inst); Deciphera (Inst); Duality Biologics (Inst); eFFECTOR Therapeutics (Inst); Eisai (Inst); Ellipses Pharma (Inst); Elucida Oncology (Inst); EMD Serono (Inst); Fochon Pharmaceuticals (Inst); Fujifilm (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); H3 Biomedicine (Inst); Harpoon (Inst); Hutchison MediPharma (Inst); Immunogen (Inst); Immunomedics (Inst); Incyte (Inst); Infinity Pharmaceuticals (Inst); Inspirna (Inst); InventisBio (Inst); Jacobio (Inst); K-Group Beta (Inst); Karyopharm Therapeutics (Inst); Kind Pharmaceuticals (Inst); Leap Therapeutics (Inst); Lilly (Inst); Loxo (Inst); Lycera (Inst); MabSpace Biosciences (Inst); Macrogenics (Inst); MedImmune (Inst); Mersana (Inst); Merus (Inst); Millennium (Inst); Molecular Templates (Inst); Myriad Genetics (Inst); Novartis (Inst); Nucana (Inst); Olema Pharmaceuticals (Inst); OncoMed (Inst); Oncothyreon (Inst); ORIC Pharmaceuticals (Inst); Orinove (Inst); Orum Therapeutics (Inst); Pfizer (Inst); PharmaMar (Inst); Pieris Pharmaceuticals (Inst); Pionyr (Inst); Plexxikon (Inst); Prelude Therapeutics (Inst); ProfoundBio (Inst); Radius Health (Inst); Regeneron (Inst); Relay Therapeutics (Inst); Repertoire Immune Medicines (Inst); Rgenix (Inst); Seagen (Inst); Sermonix Pharmaceuticals (Inst); Shattuck Labs (Inst); Silverback Therapeutics (Inst); Stem CentRx (Inst); Stemline Therapeutics (Inst); Sutro Biopharma (Inst); Syndax (Inst); Syros Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst); TapImmune Inc. (Inst); Tesaro (Inst); Tolmar (Inst); Torque (Inst); Treadwell Therapeutics (Inst); Verastem (Inst); Zenith Epigenetics (Inst); Zymeworks (Inst)
 
Michelino De Laurentiis
Stock and Other Ownership Interests - Arvinas
Honoraria - AstraZeneca; Daiichi Sankyo Europe GmbH; Exact Sciences; Gilead Sciences; Ipsen; Lilly; MSD; Novartis; Pfizer; Pierre Fabre; Roche; Seagen; TOMA Biosciences; Veracyte
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo Europe GmbH; Gilead Sciences; Ipsen; Lilly; MSD; Novartis; Pfizer; Pierre Fabre; Roche; Seagen
Speakers' Bureau - Novartis
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Genzyme (Inst); Lilly; MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
 
Komal Jhaveri
Consulting or Advisory Role - Abbvie; AstraZeneca; Bicycle Therapeutics; Biotheranostics; BluePrint Medicines; Bristol-Myers Squibb; Daiichi Sankyo; Eisai; Genentech; Gilead Sciences; Lilly; Novartis; Pfizer; Sanofi; Scorpion Therapeutics; Seagen
Research Funding - AstraZeneca (Inst); Blueprint Medicines (Inst); Context Therapeutics (Inst); Genentech (Inst); Gilead Sciences (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); RayzeBio (Inst); Scorpion Therapeutics (Inst); VelosBio/Merck (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Genentech/Roche; Gilead Sciences; Intellisphere; Jounce Therapeutics; Lilly; Pfizer; Taiho Pharmaceutical
 
Xichun Hu
Honoraria - AstraZeneca; Daiichi Sankyo/Lilly; Eisai; Hengrui Pharmaceutical; Lilly; Merck; Novartis; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca
 
Sylvain Ladoire
Research Funding - Eisai (Inst); Novartis (Inst)
Expert Testimony - Astellas Pharma; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Ipsen; Janssen Oncology; Lilly; Menarini; Novartis; Pfizer; Roche; Sanofi; Seagen
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Ipsen; Janssen Oncology; Novartis; Pfizer; Sanofi; seagen
 
Anne Patsouris
Honoraria - Gilead Sciences (Inst)
Consulting or Advisory Role - AstraZeneca (Inst); Gilead Sciences (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Eisai; Eisai; NOVARTIS; NOVARTIS; Pfizer; Roche
 
Claudio Zamagni
Consulting or Advisory Role - AstraZeneca; Celgene; Daichi-Sankyo; EISAI; Exact Sciences; Gilead Sciences; GlaxoSmithKline; Lilly; Menarini; MSD Oncology; Novartis; Pfizer; Roche; Seagen
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Daiichi Sankyo (Inst); Gilead Sciences (Inst); Greenwich LifeSciences (Inst); Immunogen (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Medivation (Inst); Merck (Inst); Morphotek (Inst); MSD Oncology (Inst); Novartis (Inst); pfizer (Inst); Roche (Inst); Roche/Genentech (Inst); Seagen (Inst); Synthon (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Daichi-Sankyo; Gilead Sciences; MSD Oncology; Novartis; Pfizer; Roche
 
Jiuwei Cui
No Relationships to Disclose
 
Marina Cazzaniga
Honoraria - Pierre Fabre
Consulting or Advisory Role - Pierre Fabre
Speakers' Bureau - Helsinn Healthchare
Research Funding - Eisai (Inst); Lilly (Inst); Pfizer (Inst)
 
Timucin Cil
Consulting or Advisory Role - AstraZeneca; BMS Turkey; Merck
Speakers' Bureau - Lilly; Pfizer; Takeda
 
Katarzyna Jerzak
Honoraria - Amgen; Apobiologix; AstraZeneca; Daiichi Sankyo/Astra Zeneca; Eisai; Exact Sciences; Gilead Sciences; Knight Therapeutics; Lilly; Merck; Merck; Myriad Genetics; Novartis; Pfizer; Roche; Seagen; Viatris
Consulting or Advisory Role - Amgen; Apobiologix; AstraZeneca; Daiichy Sankyo; Eisai; Genomic Health; Gilead Sciences; Knight Therapeutics; Lilly; Merck; Myriad Genetics; Novartis; Pfizer; Roche; Seagen; Viatris
Research Funding - AstraZeneca; Lilly; Seagen
Patents, Royalties, Other Intellectual Property - I am the lead inventor on a patent for the use of dronedarone and its structural derivatives as cancer therapies.
Travel, Accommodations, Expenses - Agendia; AstraZeneca/Daiichi Sankyo
Other Relationship - Viatris
 
Christian Fuentes
No Relationships to Disclose
 
Tetsuhiro Yoshinami
Honoraria - AstraZeneca; Chugai Pharma; Eisai; Kyowa Kirin International; Lilly Japan; MSD; MSD; Pfizer
 
Álvaro Rodríguez-Lescure
Consulting or Advisory Role - AstraZeneca Spain; DAICHII-SANKYO; Lilly; MSD; Novartis; Pfizer; Pierre Fabre; Roche; SEAGEN
Speakers' Bureau - AstraZeneca Spain; DAICHII-SANKYO; Lilly; Novartis; Pfizer; Roche; SEAGEN
Research Funding - AstraZeneca Spain (Inst); BRISTOL-MYERS SQUIBB (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); Radius Health (Inst); Roche (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - Pfizer; Roche
 
Olga Valota
Stock and Other Ownership Interests - Pfizer
 
Dongrui Lu
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Marcella Martignoni
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Janaki Parameswaran
Employment - Arvinas
Stock and Other Ownership Interests - Arvinas; Bristol-Myers Squibb/Celgene
 
Xin Zhi
Employment - Arvinas
Stock and Other Ownership Interests - Arvinas
 
Mario Campone
Honoraria - Pfizer (Inst)
Consulting or Advisory Role - Pfizer (Inst)
Speakers' Bureau - Lilly (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Novartis; Pfizer